Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy in terms of the pathological complete
response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based
regimen followed by Nab-paclitaxel and Trastuzumab in patients with HER2 positive operable
breast cancer.